K

Catalio Capital Management logo

Catalio Capital Management

Crunchbase
Pitchbook
Crunchbase

Deals on record

16

Common Fundraising Type

Series C

Character Biosciences logo
Character Biosciences

Precision medicine • Drug development

Character Biosciences is a precision medicine company focused on developing therapies for degenerative eye diseases, particularly age-related macular degeneration.

Series B
$93M
03/25/2025
Article
Perceive Pharma logo
Perceive Pharma

Pharmaceutical • Neuroprotective

Retinal Degeneration Fund logo
Johnson & Johnson logo
GV logo
Deerfield Management logo

Perceive Pharma develops novel small molecule neuroprotective therapeutics for ophthalmic diseases, including glaucoma.

Series A
$15M
02/18/2025
Article
PinkDx logo
PinkDx

Diagnostic • Gynecologic Cancer

BEVC logo
Sandbox Clinical Ventures logo
Blue Venture Fund logo
Catalio Capital Management logo

PinkDx develops advanced diagnostic tests for gynecologic cancer to improve women's healthcare outcomes.

Series A
$5M
01/23/2025
Article
Aviceda Therapeutics logo
Aviceda Therapeutics

Biotech • Immunomodulators

TCGX logo
Omega Funds logo
Jeito Capital logo
Enavate Sciences logo

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOS™ nanotechnology platform.

Series C
$207.5M
01/07/2025
Article
Alentis Therapeutics logo
Alentis Therapeutics

Biotech • Clinical-stage

Jeito Capital logo
Novo Holdings logo
OrbiMed logo
RA Capital Management logo

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

Series D
$181.4M
11/12/2024
Article
Orasis Pharmaceuticals logo
Orasis Pharmaceuticals

Corrective eye drops • Presbyopia treatment

Arboretum Ventures logo
Visionary Ventures logo
Sequoia Capital logo
SBI logo

Orasis Pharmaceuticals develops and commercializes corrective eye drops for treating presbyopia in adults.

Hybrid D
$83M
10/08/2024
Article
Noetik logo
Noetik

AI • Biotech

Polaris Partners logo
Zetta Venture Partners logo
Wittington Ventures logo
North South Ventures logo

Noetik is an AI-native biotech company that leverages spatial omics data and high-throughput CRISPR technology to develop precision oncology therapies.

Series A
$40M
08/29/2024
Article
Lassen Therapeutics logo
Lassen Therapeutics

Clinical-stage biotech • IL-11 receptor

Longitude Capital logo
Longwood Capital logo
Frazier Life Sciences logo
Catalio Capital Management logo

Lassen Therapeutics is a clinical-stage biotech company developing novel treatments for fibro-inflammatory diseases and cancer, focusing on therapies targeting the IL-11 and IL-18 pathways.

Series B
$85M
12/19/2023
Article
Odyssey Therapeutics logo
Odyssey Therapeutics

Biotechnology • Immunomodulators

Woodline Partners logo
Walleye Capital logo
Leerink Partners logo
The Global BioAccess Fund logo

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

Series C
$101M
12/05/2023
Article
RefleXion Medical logo
RefleXion Medical

Therapeutic Oncology • Solid Tumor Cancer Treatment

Venrock logo
TPG logo
T.Rowe Price Associates logo
Square Point Capital logo

RefleXion Medical develops and commercializes SCINTIX therapy, a novel treatment for all stages of indicated solid tumor cancers, including metastatic disease, delivered via the RefleXion X1 platform.

Equity
$105M
11/15/2023
Article
Sanguine Biosciences logo
Sanguine Biosciences

Biospecimen Procurement • Apheresis Donation Center

Catalio Capital Management logo

Sanguine Biosciences is a biospecimen procurement services company that empowers patients to accelerate precision medicine and cell and gene therapy research and development.

Debt
$10M
10/31/2023
Article

Series B
$100M
10/03/2023
Article
Avalyn Pharma logo
Avalyn Pharma

Biopharmaceutical • Respiratory Diseases

Perceptive Xontogeny Venture Funds logo
Wellington Management logo
Vida Ventures logo
T. Rowe Price Associates logo

Avalyn Pharma is a biopharmaceutical company that develops inhalation therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases, with a focus on creating new inhaled formulations of approved medicines.

Series C
$175M
09/27/2023
Article
Noetik logo
Noetik

AI • Biotech

Zetta Venture Partners logo
DCVC logo
North South Ventures logo
Intermountain Ventures logo

Noetik is an AI-native biotech company that leverages spatial omics data and high-throughput CRISPR technology to develop precision oncology therapies.

Seed
$14M
09/07/2023
Article
Star Therapeutics logo
Star Therapeutics

Biotechnology • Antibody Therapies

Sofinnova Investments logo
Westlake Village BioPartners logo
OrbiMed logo
Redmile Group logo

Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.

Series C
$90M
09/05/2023
Article
TapestryHealth logo
TapestryHealth

Healthcare • Life Sciences

Catalio Capital Management logo

TapestryHealth is a nationwide multi-specialty healthcare company that uses advanced radar technology and AI to evaluate and treat patients in skilled nursing facilities and other post-acute environments, aiming to deliver fully integrated care and improve patient outcomes.

Debt
$25M
08/29/2023
Article